Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FL5TV
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,547
Award facts
- Contract value 100% obligated
- $1,547.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency for 150 mg/ml Xolair syringes valued at $1,547.40. This firm fixed-price delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a specific pharmaceutical product requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The award carries no set-aside designation, allowing the vendor to compete on its merits as a woman-owned small business in the federal marketplace. Xolair (omalizumab) is a monoclonal antibody biologic medication used primarily in treating moderate-to-severe asthma and allergic conditions, supporting the Department of Defense's pharmaceutical supply chain for military healthcare facilities.
This delivery order is part of DMS Pharmaceutical Group's significant engagement with the Defense Logistics Agency, which has awarded the company a substantial single-award Indefinite Delivery Contract valued at $499,999,999 and valid through November 2026 under the SPE2DB program. This overarching contract establishes the framework through which the agency issues firm fixed-price delivery orders for comprehensive pharmaceutical products supporting medical supply needs of military health facilities worldwide, encompassing branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. DMS Pharmaceutical Group's consistent success in securing federal pharmaceutical contracts demonstrates its established role as a critical supplier within the Department of Defense's medical distribution network.
Quick answers
Who was awarded contract SPE2DB25FL5TV?
SPE2DB25FL5TV was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FL5TV worth?
The government has obligated $1,547 on SPE2DB25FL5TV.
Is contract SPE2DB25FL5TV an order under another contract?
Yes. SPE2DB25FL5TV is a delivery order under SPE2DB22D9209, an indefinite delivery contract.
Was contract SPE2DB25FL5TV competed?
The extent of competition for SPE2DB25FL5TV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award